Core Viewpoint - ST Tian Sheng (002872) announced that it and its wholly-owned subsidiary Hubei Tian Sheng Pharmaceutical participated in the national organized procurement of drugs, with three products included in the proposed selection list [1] Group 1: Selected Products - The selected products include Paracetamol Tablets, Lidocaine Hydrochloride Injection, and Furosemide Injection, which are commonly used in clinical settings for treating symptoms such as fever, pain relief, local anesthesia, arrhythmias, and edema-related diseases [1] - The final selection results will be confirmed by the procurement office's official announcement [1] Group 2: Market Impact - The company stated that if procurement contracts are signed and implemented smoothly, it will help expand the sales range of the relevant products, enhance market share, and increase brand influence [1] - The company also cautioned that the procurement contracts have not yet been signed, and there is uncertainty regarding the subsequent progress and actual impact on the company [1]

Group 1 - The core viewpoint of the articles highlights that ST Tian Sheng (002872) is facing additional risk warnings due to historical fund misappropriation by its controlling shareholder and penalties from the China Securities Regulatory Commission [1] - The company and its subsidiaries have three products that are likely to be selected for the national drug procurement program, which could expand their sales scope and increase market share if contracts are finalized [1] Group 2 - In the past week, ST Tian Sheng's stock price has increased by 7.82%, with a single-day increase of 2.14% on February 11, closing at 5.24 yuan [2] - Technical indicators show that the stock price has broken through the 20-day moving average, and the MACD indicator has turned positive, indicating a stronger short-term performance compared to the pharmaceutical sector [2]

Group 1 - The company and its subsidiary, Hubei Tiensheng Pharmaceutical Co., Ltd., participated in the national organized procurement for drugs whose agreements have expired, and some products are proposed to be selected for this procurement [1] - If the procurement contracts are signed and implemented, it will help expand the sales range of the relevant products, increase market share, and enhance brand influence [1] Group 2 - The announcement was made on February 11, 2026, by the board of directors of Tiensheng Pharmaceutical Group Co., Ltd. [2]

Core Viewpoint - ST Tian Sheng (002872.SZ) and its wholly-owned subsidiary Hubei Tian Sheng Pharmaceutical Co., Ltd. are participating in the national organized procurement for drugs whose agreements have expired, with some products expected to be selected in the upcoming procurement process [1] Group 1 - The company and Hubei Tian Sheng are involved in the national organized procurement for drugs as the agreement period has expired [1] - The proposed selection of the company's products in the procurement will potentially enhance sales scope, market share, and brand influence if contracts are signed and implemented [1]

协议期满品种接续采购拟中选的公告 证券代码：002872 证券简称：ST 天圣 公告编号：2026-007 天圣制药集团股份有限公司 关于公司及子公司参加国家组织集采药品 一、拟中选产品情况 注：上述信息均以国家组织集采药品协议期满品种接续采购办公室发布的最终结果为准。 二、此次拟中选对公司的影响 特此公告！ 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 天圣制药集团股份有限公司(以下简称"公司")及全资子公司湖北天圣药业 有限公司（以下简称"湖北天圣"）参加了国家组织集采药品协议期满品种接续 采购工作。根据国家组织集采药品协议期满品种接续采购办公室于 2026 年 2 月 10 日发布的《国家组织集采药品协议期满品种接续采购拟中选结果公示》，公 司及湖北天圣部分产品拟中选本次接续采购。现将相关情况公告如下： | 拟中选企业 | 拟中选产品名称 | 适应症 | | --- | --- | --- | | 天圣制药集团 | | 用于普通感冒或流行性感冒引起的发热，也用于缓解 | | 股份有限公司 | 对乙酰氨基酚片 | 轻至中度疼痛如头痛、关节痛、偏头痛、牙痛 ...

Core Viewpoint - ST Tian Sheng (002872.SZ) announced that its controlling shareholder, Liu Qun, misappropriated company funds amounting to 125 million yuan, which has been fully repaid as of April 8, 2021 [1] Group 1: Financial Misconduct - The company is under additional risk warnings due to the misappropriation case and administrative penalties from the China Securities Regulatory Commission (CSRC) [1] - On November 7, 2025, the company received an administrative penalty decision from the Chongqing Securities Regulatory Bureau, which involved false reporting of financial indicators in its annual report [1] Group 2: Audit Concerns - The auditor issued a qualified opinion on the 2024 financial report, stating that the integrity of related party fund usage could not be confirmed [1]

天圣制药集团股份有限公司 证券代码：002872 证券简称：ST 天圣 公告编号：2026-005 关于公司股票交易被实行其他风险警示 相关事项的进展公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有 虚假记载、误导性陈述或重大遗漏。 特别提示： 1、因控股股东涉嫌侵占公司资金触发其他风险警示，根据《深圳证券交易 所股票上市规则》相关规定，天圣制药集团股份有限公司（以下简称"公司" 或"天圣制药"）股票交易自 2019 年 6 月 5 日起被实施其他风险警示。 2、公司分别于 2025 年 9 月 12 日、2025 年 11 月 7 日收到了中国证券监督 管理委员会重庆监管局（以下简称"重庆证监局"）出具的《行政处罚事先告 知书》（处罚字（2025）4 号）、《行政处罚决定书》（（2025）4 号）。根据 《深圳证券交易所股票上市规则》第 9.8.1 条第（八）项规定，公司股票交易自 2025 年 9 月 15 日起被叠加实施其他风险警示。 一、实施其他风险警示的主要原因 1、控股股东刘群涉嫌侵占公司资金，由于刘群部分涉案财物已扣押、冻结、 查封，预计无法在一个月内将占用公司的资金归还。根 ...

证券代码：002872 证券简称：ST 天圣 公告编号：2026-006 天圣制药集团股份有限公司 关于公司申请授信接受关联方担保暨关联交易的进展公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 一、担保情况概述 债权人：兴业银行股份有限公司重庆分行 保证人：刘爽 债务人：天圣制药集团股份有限公司 天圣制药集团股份有限公司（以下简称"公司"）于 2025 年 4 月 25 日召开 了第六届董事会第十一次会议、于 2025 年 5 月 23 日召开了 2024 年度股东大会， 审议通过了《关于公司及子公司向银行申请授信提供担保并接受关联方担保暨关 联交易的议案》。同意公司向兴业银行股份有限公司重庆分行（简称"兴业银行 重庆分行"）申请授信 3,000 万元，公司以自有房产为该笔授信提供抵押担保， 公司关联方刘爽先生为该笔授信提供连带责任保证担保。具体内容详见公司于 2025 年 4 月 29 日披露的《关于公司及子公司向银行申请授信提供担保并接受关 联方担保暨关联交易的公告》（公告编号：2025-023）。 二、本次担保的进展情况 近日，公司与兴业银行重庆分 ...

Group 1 - The company expects a net loss for the fiscal year 2025, with the performance forecast period from January 1, 2025, to December 31, 2025 [1] - The financial data related to the performance forecast has not been audited by the accounting firm, but preliminary communication indicates no significant discrepancies [1][2] Group 2 - The primary reason for the expected loss is high fixed costs, particularly depreciation expenses on fixed assets [2] - The company anticipates a reduction in losses compared to the previous year, mainly due to a decrease in the provision for impairment of fixed assets [2]

Core Viewpoint - ST Tian Sheng (002872.SZ) is forecasting a net loss for the fiscal year 2025, with expected losses ranging from 52 million to 76 million yuan, compared to a loss of 87.4 million yuan in the same period last year [1] Financial Performance - The projected net loss attributable to shareholders is between 52 million and 76 million yuan for 2025, which is an improvement from the previous year's loss of 87.4 million yuan [1] - The net profit after deducting non-recurring gains and losses is expected to be a loss of 60 million to 88 million yuan, compared to a loss of 110 million yuan in the previous year [1] Reasons for Loss - The primary reason for the company's losses is attributed to high fixed costs, particularly depreciation expenses related to fixed assets [1] - The anticipated reduction in losses for 2025 is mainly due to a decrease in the provision for fixed asset impairment compared to the previous year [1]